CA-SMARTFRAME
13.2.2024 15:15:33 CET | Business Wire | Press release
Truepic, provider of secure content transparency infrastructure, and SmartFrame Technologies, a leading UK-based tech provider that is redefining the digital image standard, have deployed the first secure image protection model that is set to redefine the landscape of authenticity and uncompromised security with provenance in the global sports photography space.
SmartFrame, with its innovative image-streaming technology, has made substantial strides in ensuring the integrity and ownership of media collections. Photos backed by Truepic's trusted certificate authority undergo a seamless and secure verification process that compliantly signs SmartFrame's visual media at scale. Every image is equipped with the Coalition for Content Provenance and Authenticity’s (C2PA) Content Credentials, marking sports brands’ assets as authentic and providing a trusted source of information for online viewers.
Recognizing the importance of ensuring transparency and authenticity online, multiple sports enterprises and brands, such as Six Nations Rugby, New Zealand Rugby, and Manchester City F.C. have embraced SmartFrame’s image-streaming distribution model, supported by Truepic’s certificate authority. These premier sports organizations are elevating global brand protection while simultaneously contributing to a safer and more reliable online image ecosystem within sports photography. Furthermore, by adopting secure image streaming and embedding C2PA Content Credentials, they are setting a benchmark for how digital images are originated, published, consumed, and monetized online. This strategic move aligns with the critical need for enhanced security in the contextual advertising market, projected to reach over $500 billion by 2030, which sports enterprises can take advantage of to help ensure their continued profitability.
“SmartFrame and Truepic’s partnership represents a significant leap forward in digital media integrity,” said Jeffrey McGregor, CEO of Truepic. “SmartFrame’s cutting edge image-streaming network paired with Truepic’s authenticity infrastructure introduces the most efficient way for commercial partners to assure the integrity and ownership of media collections. We are proud to partner with a forward-thinking organization like SmartFrame on industry leading content integrity products.”
"As a fellow member of the C2PA, it's clear that the need for trust, security, and transparency in online visual content is as critical to SmartFrame as it is to Truepic,” explains Rob Sewell, CEO of SmartFrame Technologies. “This shared vision forms the cornerstone of our partnership. By integrating Truepic's widely respected authentication technology into our secure image publishing network, we gain the capability to authenticate images swiftly and effectively, and to provide users with a seamless and trustworthy experience. This collaboration marks the next phase in our mission to provide the highest level of protection and transparency for online content, and we are excited to embark on this journey with a company as esteemed as Truepic."
About Truepic
Truepic provides authenticity infrastructure for the internet. The company’s transparency tools deliver verifiable information about the origin and editing history of digital content. Truepic is dedicated to advancing products and services that establish transparency in digital content, empowering viewers and users to identify authenticity and differentiate human from computer-generated. Recognized as one of TIME’s Best Inventions and Fast Company’s World Changing Ideas, consumers, businesses, creators, and publishers trust Truepic’s technologies to make informed decisions. For more information, visit truepic.com.
About SmartFrame Technologies
Founded in 2015, SmartFrame Technologies is a London-based technology provider whose image streaming platform redefines the standard for online image publishing. It unites sports brands and other content owners with publishers, advertisers, and online audiences, and ensures that images are delivered in the highest quality with maximum security, clear provenance, and detailed analytics. Furthermore, through its contextual ad tech component, brands can reach audiences with high-impact, contextually targeted, in-image advertising and sponsorship placements in a way that recognizes the interests of its viewers and simultaneously complies with global privacy regulations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213285238/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom